Key result
Nonfemoral TAVR access linked to ~291% higher 30-day mortality versus femoral access in frail adults.
Why the study?
Frailty may influence outcomes and tolerance of more invasive nonfemoral TAVR procedures in older adults, but the interaction with access site risk was unclear.
Does nonfemoral access increase 30-day and 12-month mortality in frail older adults undergoing TAVR compared to femoral access?
Cohort (n=723)
Yes
Does nonfemoral access increase 30-day and 12-month mortality in frail older adults undergoing TAVR compared to femoral access?
Odds Ratio: 3.91 (95% CI 1.48–10.31)
Frail older adults undergoing TAVR via nonfemoral access have a substantially higher risk of 30-day mortality compared to femoral access, whereas nonfrail patients tolerate either approach with similar short-term risk.
Nonfemoral access may raise short-term mortality in frail TAVR patients; leaves open frailty-guided access selection pending randomized data.
OBJECTIVES: The authors sought to determine whether frail older adults undergoing nonfemoral transcatheter aortic valve replacement (TAVR) procedures had a higher risk of 30-day and 12-month mortality. BACKGROUND: Frailty can help predict outcomes and guide therapy in older adults being considered for TAVR. Nonfemoral TAVR procedures are more invasive and impart a greater risk of adverse events, which may be less well tolerated in frail patients, compared with transfemoral TAVR procedures. METHODS: This study was a post hoc analysis of the FRAILTY-AVR (Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions) prospective multicenter cohort that consisted of older adults undergoing TAVR from 2012 to 2017. Frailty was assessed using the Essential Frailty Toolset (EFT). Endpoints of interest were 30-day and 12-month all-cause mortality. Interaction tables and multivariable logistic regression models were used to investigate statistical interaction on the additive and multiplicative scales. RESULTS: The cohort consisted of 723 patients with a mean age of 84 ± 6 years, of which 556 (77%) had femoral access and 167 (23%) had nonfemoral access. In frail patients with EFT scores ≥3 (35%), nonfemoral access was associated with increased 30-day mortality (odds ratio [OR]: 3.91; 95% confidence interval [CI]: 1.48 to 10.31); whereas in nonfrail patients with EFT scores <3 (65%), nonfemoral access had no effect (OR: 1.29; 95% CI: 0.34 to 4.94). There was statistical evidence of interaction between frailty and access site on 30-day mortality on the additive scale (relative excess risk due to interaction = 5.95). Nonfemoral access was associated with increased 1-year mortality in frail patients (OR: 1.98; 95% CI: 1.00 to 3.93) but not in nonfrail patients (OR: 1.83; 95% CI: 0.90 to 3.74), although there was no statistical evidence of interaction. CONCLUSIONS: Frail patients undergoing TAVR via a more invasive nonfemoral access face a substantially higher risk of 30-day mortality, whereas nonfrail older adults tolerate the procedure with a low short-term risk irrespective of access route.
No takes yet. Share an insight, caveat, or question.
Drudi et al. (2018) conducted a cohort in older adults undergoing TAVR (n=723). Nonfemoral access vs. Femoral access was evaluated on 30-day all-cause mortality (OR 3.91, 95% CI 1.48 to 10.31). In frail older adults undergoing TAVR, nonfemoral access was associated with a significantly increased risk of 30-day mortality compared to femoral access (OR 3.91; 95% CI 1.48-10.31).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: